Australian Urology Associates Trials

Australian Urology Associates	Welcome, Profile Billing Logout

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Cescon, Terrence

XPORT-MM-031, NCT05028348 / 2021-001691-41: A Study of Combination of Selinexor, Pomalidomide, and Dexamethasone (SPd) Versus Elotuzumab, Pomalidomide, and Dexamethasone (EloPd) in Subject With Previously Treated Multiple Myeloma

	Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
	Jul 2024 - Dec 2024 : H2'24 - Market entry in Malaysia in combination with bortezomib and dexamethasone for r/r MM

Recruiting

222

Europe, US

Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral

Stichting European Myeloma Network, Karyopharm Therapeutics Inc

Multiple Myeloma

03/26

03/29

CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

Anatomic Stage IA Breast Cancer AJCC V8, Anatomic Stage II Breast Cancer AJCC V8, Anatomic Stage IIA Breast Cancer AJCC V8, Anatomic Stage IIB Breast Cancer AJCC V8, Anatomic Stage III Breast Cancer AJCC V8, Anatomic Stage IIIA Breast Cancer AJCC V8, Anatomic Stage IIIB Breast Cancer AJCC V8, Anatomic Stage IIIC Breast Cancer AJCC V8, HER2 Positive Breast Carcinoma, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Prognostic Stage I Breast Cancer AJCC V8, Prognostic Stage IA Breast Cancer AJCC V8, Prognostic Stage IB Breast Cancer AJCC V8, Prognostic Stage II Breast Cancer AJCC V8, Prognostic Stage IIA Breast Cancer AJCC V8, Prognostic Stage IIB Breast Cancer AJCC V8, Prognostic Stage III Breast Cancer AJCC V8, Prognostic Stage IIIA Breast Cancer AJCC V8, Prognostic Stage IIIB Breast Cancer AJCC V8, Prognostic Stage IIIC Breast Cancer AJCC V8, Synchronous Bilateral Breast Carcinoma

01/28

05/35

CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting

2/3

1912

Canada, US

Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month

NRG Oncology, Natera, Inc., National Cancer Institute (NCI)

Stage III Colon Cancer

03/29

03/30

VOICE, NCT04648020 / 2021-000999-11: Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.

Terminated

190

Europe, US

Clonidine HCl Mucoadhesive Buccal Tablet, Validive®, Placebo Mucoadhesive Buccal Tablet

Monopar Therapeutics, Monopar Therapeutics Inc.

Chemoradiotherapy-Induced Severe Oral Mucositis

05/23

VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting

102

Europe, Canada, US, RoW

DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan

ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC

Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma

10/24

04/25

MRD, NCT05210283: CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

Recruiting

N/A

750

Canada, US

MRD

Exact Sciences Corporation, NSABP Foundation Inc

Colorectal Cancer

02/28

Grummet, Jeremy

Biolen-PC, NCT04284761: A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Completed

US, RoW

Bicalutamide implant

Alessa Therapeutics Inc.

Prostate Adenocarcinoma, Lower Urinary Tract Symptoms

05/23

Frydenberg, Mark

ZIRCON, NCT03849118 / 2018-002773-21: 89Zr-TLX250 for PET/CT Imaging of ccRCC- Study

Completed

300

Europe, Canada, US, RoW

89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX)

Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd

Clear Cell Renal Cell Carcinoma

10/22

11/22

Moon, Daniel

Biolen-PC, NCT04284761: A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Completed

US, RoW

Bicalutamide implant

Alessa Therapeutics Inc.

Prostate Adenocarcinoma, Lower Urinary Tract Symptoms

05/23

Trial + Data / Events

Status

Region

Interventions

Sponsor

Conditions

Primary compl

Study compl

Cescon, Terrence

	Jul 2024 - Dec 2024: Top-line data from XPORT-MM-031 trial in combination with pomalidomide and dexamethasone for multiple myeloma
	Jul 2024 - Dec 2024 : H2'24 - Market entry in Malaysia in combination with bortezomib and dexamethasone for r/r MM

Recruiting

222

Europe, US

Selinexor, KPT-330, Elotuzumab, Pomalidomide, Dexamethasone Oral

Stichting European Myeloma Network, Karyopharm Therapeutics Inc

Multiple Myeloma

03/26

03/29

CompassHER2 RD, NCT04457596: T-DM1 and Tucatinib Compared with T-DM1 Alone in Preventing Relapses in People with High Risk HER2-Positive Breast Cancer, the Trial

Jan 2028 - Dec 2028: From CompassHER2 RD trial in combination with Kadcyla for HER2+ breast cancer

Recruiting

1031

Canada, US

Trastuzumab Emtansine, Placebo Administration, Tucatinib, Questionnaire Administration, Quality-of-Life Assessment

Alliance for Clinical Trials in Oncology, National Cancer Institute (NCI), Seagen Inc.

01/28

05/35

CIRCULATE-US, NCT05174169: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease

Recruiting

2/3

1912

Canada, US

Signatera test, mFOLFOX6 3-6 month, CAPOX 3 month, mFOLFIRINOX, mFOLFOX6 6 month, CAPOX 6 month

NRG Oncology, Natera, Inc., National Cancer Institute (NCI)

Stage III Colon Cancer

03/29

03/30

VOICE, NCT04648020 / 2021-000999-11: Clonidine HCl MBT vs. Placebo to Prevent Chemoradiotherapy-Induced Severe Oral Mucositis in Oropharyngeal Cancer.

Terminated

190

Europe, US

Clonidine HCl Mucoadhesive Buccal Tablet, Validive®, Placebo Mucoadhesive Buccal Tablet

Monopar Therapeutics, Monopar Therapeutics Inc.

Chemoradiotherapy-Induced Severe Oral Mucositis

05/23

VITALIZE, NCT04920617 / 2021-003712-27: DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Recruiting

102

Europe, Canada, US, RoW

DPX-Survivac, maveropepimut-S, Pembrolizumab, MK-3475, Keytruda, CPA, Intermittent, low-dose cyclophosphamide, Procytox, Cytoxan

ImmunoVaccine Technologies, Inc. (IMV Inc.), Merck Sharp & Dohme LLC

Relapsed Diffuse Large B-cell Lymphoma, Refractory Diffuse Large B-cell Lymphoma

10/24

04/25

MRD, NCT05210283: CORRECT Study of Minimal Residual Disease Detection in Colorectal Cancer

Recruiting

N/A

750

Canada, US

MRD

Exact Sciences Corporation, NSABP Foundation Inc

Colorectal Cancer

02/28

Grummet, Jeremy

Biolen-PC, NCT04284761: A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Completed

US, RoW

Bicalutamide implant

Alessa Therapeutics Inc.

Prostate Adenocarcinoma, Lower Urinary Tract Symptoms

05/23

Frydenberg, Mark

ZIRCON, NCT03849118 / 2018-002773-21: 89Zr-TLX250 for PET/CT Imaging of ccRCC- Study

Completed

300

Europe, Canada, US, RoW

89Zr-girentuximab, 89Zr-TLX250, 89Zr-DFO-TFP-girentuximab (GTX)

Telix Pharmaceuticals (Innovations) Pty Limited, Telix International Pty Ltd

Clear Cell Renal Cell Carcinoma

10/22

11/22

Moon, Daniel

Biolen-PC, NCT04284761: A Study to Establish the Feasibility of Biolen for the Local Delivery of Bicalutamide in Patients With Prostate Cancer

Completed

US, RoW

Bicalutamide implant

Alessa Therapeutics Inc.

Prostate Adenocarcinoma, Lower Urinary Tract Symptoms

05/23



	Diseases Companies Products Productz Mechanisms of Action Sites